- $525.08m
- $228.05m
- $0.04m
Altimmune rises on plans to test obesity drug for alcohol use disorder, other conditions
Brief: Altimmune Inc Phase 2 AUD Trial For Pemvidutide Expected In Q2 2025
Altimmune to test obesity drug for alcohol use disorder and related health conditions
Altimmune gains on plans to test weight-loss drug for alcohol use disorder, other conditions
U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp
Brief: Altimmune Files For Mixed Shelf Offering Of Up To $400 Million- SEC Filing
Altimmune Inc reports results for the quarter ended December 31 - Earnings Summary
Factbox: Fat, not muscle: drugmakers in race for next weight-loss breakthrough
Viking set to double in 'challenging' year for obesity drug developers
Viking set to double in 'challenging' year for obesity drug developers
U.S. STOCKS ON THE MOVE-Spire, Copper miners, Abercrombie & Fitch
U.S. STOCKS ON THE MOVE-Mission Produce, Sirius XM, Carnival Corp
Factbox: Weight-loss drug developers line up to tap market worth $150 billion
U.S. STOCKS ON THE MOVE-Humacyte, Ionis Pharmaceuticals, Emeren Group
U.S. STOCKS ON THE MOVE-FedEx, Eli Lilly, Aadi Bioscience
Weight-loss drug developers gain after Novo's obesity drug underperforms in study
U.S. STOCKS ON THE MOVE-Darden Restaurants, Natgas firms, Affirm Holdings
U.S. STOCKS ON THE MOVE-Paychex, RTX, Boeing
U.S. STOCKS ON THE MOVE-Oklo, Okta, Zoom